Cormedix Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cormedix Inc. on December 24, 2012, reporting events occurring on December 18, 2012, and December 21, 2012. The filing details significant changes to the company's executive leadership structure effective January 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on corporate governance and personnel changes.
Material Changes
The following executive changes were announced:
- Departure of Chief Medical Officer: Dr. Mark A. Klausner was notified on December 18, 2012, that his employment agreement will not be renewed upon its expiration on February 28, 2013.
- Appointment of Acting Chief Scientific Officer: Dr. Antony E. Pfaffle, a current director, was appointed Acting Chief Scientific Officer effective January 1, 2013. He will be compensated at $200 per hour.
- Appointment of Chief Executive Officer: Randy Milby, previously Chief Operating Officer, was appointed CEO effective January 1, 2013. His role as COO will terminate at that time. His consulting agreement with MW Bridges LLC was amended to extend his term to June 30, 2013, with compensation arrangements remaining unchanged.
- Appointment of Chief Financial Officer: Richard M. Cohen, currently Executive Chairman and Interim CFO, was appointed CFO effective January 1, 2013. He will earn $7,500 per month for this role and has agreed to forgo director fees during this period.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks and contingencies. The primary focus is the transition of leadership roles.
Key Facts for Investor Verification
- Verify the effective dates of the new executive appointments (January 1, 2013).
- Confirm the termination date of Dr. Klausner's employment (February 28, 2013).
- Review the amended consulting agreement with MW Bridges LLC for details on Mr. Milby's compensation, which is referenced but not detailed in this filing.
- Note that Mr. Cohen will forgo director fees while serving as CFO.